Bioventix
BVXP · AIM · Health Care · mcap £88m today
All announcements
-
24 Jun 26Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the Company was notified that earlier today Bruce Hiscock, Chief Financial...
RNS 9635132 ↗ -
18 May 26Holding(s) in CompanyRNS 9572970 ↗
-
28 Apr 26Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified today that on 27 April 2026 Bruce Hiscock,...
RNS 9542485 ↗ -
20 Apr 26Share Options Awarded
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the award on 17 April 2026 of share options over ordinary shares in the...
RNS 9528527 ↗ -
13 Apr 26Director/PDMR Shareholding Director buysRepeated director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 10 April 2026 that Ian Nicholson,...
RNS 9515725 ↗ -
08 Apr 26Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company has been notified that earlier today Peter Harrison, Chief...
RNS 9511051 ↗ -
02 Apr 26Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 2 April 2026 that on 2 April 2026 Bruce...
RNS 9506151 ↗ -
02 Apr 26Holding(s) in CompanyRNS 9505554 ↗
-
30 Mar 26
-
24 Feb 26Appointment of Non-Executive Director
Bioventix PLC (AIM: BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, is delighted to announce the appointment of Chris Yates as independent...
RNS 9443376 ↗ -
04 Dec 25Result of AGMRNS 9276823 ↗
-
26 Nov 25Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified yesterday that on 25 November 2025, Bruce...
RNS 9258324 ↗ -
18 Nov 25Holding(s) in CompanyRNS 9241198 ↗
-
11 Nov 25Posting of Annual Report and Notice of AGMRNS 9225028 ↗
-
04 Nov 25Director/PDMR Shareholding Director buysRepeated director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company has been notified that earlier today Peter Harrison, Chief...
RNS 9212210 ↗ -
30 Oct 25Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified on 29 October 2025 that Ian Nicholson,...
RNS 9202827 ↗ -
27 Oct 25Director/PDMR Shareholding Director buys
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that the Company was notified that earlier today Bruce Hiscock, Chief...
RNS 9197116 ↗ -
27 Oct 25Results for the year ended 30 June 2025
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2025.
RNS 9195153 ↗
Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.